Importer of Controlled Substances Application: Restek Corporation, 35691-35692 [2019-15738]
Download as PDF
<![CDATA[
35691
Federal Register / Vol. 84, No. 142 / Wednesday, July 24, 2019 / Notices
interest, and bonding filed in response
to the Commission Notice, the
Commission has determined that the
appropriate form of relief in this
investigation is: (1) An LEO prohibiting
the unlicensed entry of infringing roadmilling machines and components
thereof covered by one or more of claim
29 of the ’309 patent or claims 2, 5, 16,
or 23 of the ’530 patent that are
manufactured abroad for or on behalf of,
or imported by or on behalf of, any of
the Respondents or any of their
affiliated companies, parents,
subsidiaries, or other related business
entities, or their successors or assigns;
and (2) a CDO directed against
Caterpillar Paving Products, Inc. and
Caterpillar Inc., and their affiliated
companies, parents, subsidiaries, or
other related business entities, or their
successors or assigns.
The Commission has further
determined that the public interest
factors enumerated in subsections (d)(l)
and (f)(1) (19 U.S.C. 1337(d)(l), (f)(1)) do
not preclude issuance of the abovereferenced remedial orders.
Additionally, the Commission has
determined to impose a bond of
fourteen (14) percent of entered value of
the covered products during the period
of Presidential review (19 U.S.C.
1337(j)). The investigation is terminated.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, and in Part
210 of the Commission’s Rules of
Practice and Procedure, 19 CFR part
210.
By order of the Commission.
Issued: July 18, 2019.
Drug Enforcement Administration
Dated: July 15, 2019.
John J. Martin,
Assistant Administrator.
[Docket No. DEA–392]
[FR Doc. 2019–15728 Filed 7–23–19; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Importer of Controlled Substances
Application: Cardinal Health
DEPARTMENT OF JUSTICE
ACTION:
Notice of application.
Drug Enforcement Administration
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 23, 2019. Such persons
may also file a written request for a
hearing on the application on or before
August 23, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 31, 2019, Cardinal
Health, 15 Ingram Boulevard, LaVergne,
Tennessee applied to be registered as an
importer of the following basic class of
controlled substance:
DATES:
Controlled substance
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019–15689 Filed 7–23–19; 8:45 am]
BILLING CODE 7020–02–P
Drug code
Secobarbital ......
2315
Schedule
II
The company plans to only distribute
to licensed registrants for the purpose of
medical use.
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Restek Corporation
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 23, 2019. Such persons
may also file a written request for a
hearing on the application on or before
August 23, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR
1301.34(a), this is notice that on April
12, 2019, Restek Corporation, 110
Benner Circle, Bellefonte, Pennsylvania
16823–8433 applied to be registered as
an importer of the following basic class
of controlled substance:
DATES:
Drug
code
Controlled substance
khammond on DSKBBV9HB2PROD with NOTICES
Tetrahydrocannabinols ............................................................................................................................................................
VerDate Sep<11>2014
16:53 Jul 23, 2019
Jkt 247001
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
E:\FR\FM\24JYN1.SGM
24JYN1
7370
Schedule
I
35692
Federal Register / Vol. 84, No. 142 / Wednesday, July 24, 2019 / Notices
The company plans to import the
listed controlled substance in bulk for
manufacture of analytical reference
material which, in its final form, is an
exempted product.
Dated: July 15, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–15738 Filed 7–23–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: AMRI Rensselaer, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 23, 2019. Such persons
may also file a written request for a
hearing on the application on or before
August 23, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
DATES:
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR
1301.34(a), this is notice that on May 7,
2019, AMRI Rensselaer, Inc., 33
Riverside Avenue, Rensselaer, New
York 12144 applied to be registered as
an importer of the following basic class
of controlled substance:
Controlled substance
Drug code
Poppy Straw
Concentrate.
9670
Schedule
II
DEPARTMENT OF JUSTICE
[Docket No. DEA–392]
Drug Enforcement Administration Bulk
Manufacturer of Controlled
Substances Application: IsoSciences,
LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before September 23, 2019.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
The company plans to import the
listed controlled substance to
manufacture a bulk controlled substance
for distribution to its customers.
Dated: July 15, 2019.
John J. Martin,
Assistant Administrator.
In accordance with 21 CFR
1301.33(a), this is notice that on May 21,
2019, IsoSciences, LLC, 340 Mathers
Road, Ambler, Pennsylvania 19002–
3420 applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
[FR Doc. 2019–15737 Filed 7–23–19; 8:45 am]
BILLING CODE 4410–09–P
Drug
code
khammond on DSKBBV9HB2PROD with NOTICES
Controlled substance
Cathinone ................................................................................................................................................................................
Methcathinone .........................................................................................................................................................................
Lysergic acid diethylamide ......................................................................................................................................................
Marihuana ................................................................................................................................................................................
Tetrahydrocannabinols ............................................................................................................................................................
3,4-Methylenedioxyamphetamine ............................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine ...............................................................................................................................
3,4-Methylenedioxymethamphetamine ....................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine .........................................................................................................................................
Alpha-methyltryptamine ...........................................................................................................................................................
Bufotenine ................................................................................................................................................................................
Diethyltryptamine .....................................................................................................................................................................
Dimethyltryptamine ..................................................................................................................................................................
Psilocybin .................................................................................................................................................................................
Psilocyn ...................................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine .....................................................................................................................................
Dihydromorphine .....................................................................................................................................................................
Heroin ......................................................................................................................................................................................
Nicocodeine .............................................................................................................................................................................
Nicomorphine ...........................................................................................................................................................................
Normorphine ............................................................................................................................................................................
Thebacon .................................................................................................................................................................................
Normethadone .........................................................................................................................................................................
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) .........................................................................................
Para-Fluorofentanyl .................................................................................................................................................................
3-Methylfentanyl ......................................................................................................................................................................
Alpha-methylfentanyl ...............................................................................................................................................................
Acetyl-alpha-methylfentanyl .....................................................................................................................................................
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide ...............................................................................................
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) .......................................................................................
Butyryl Fentanyl .......................................................................................................................................................................
VerDate Sep<11>2014
16:53 Jul 23, 2019
Jkt 247001
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
E:\FR\FM\24JYN1.SGM
24JYN1
1235
1237
7315
7360
7370
7400
7404
7405
7431
7432
7433
7434
7435
7437
7438
7439
9145
9200
9309
9312
9313
9315
9635
9811
9812
9813
9814
9815
9816
9821
9822
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 84, Number 142 (Wednesday, July 24, 2019)]
[Notices]
[Pages 35691-35692]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-15738]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Restek Corporation
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before August 23, 2019.
Such persons may also file a written request for a hearing on the
application on or before August 23, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.34(a), this is notice that on April
12, 2019, Restek Corporation, 110 Benner Circle, Bellefonte,
Pennsylvania 16823-8433 applied to be registered as an importer of the
following basic class of controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols....................... 7370 I
------------------------------------------------------------------------
[[Page 35692]]
The company plans to import the listed controlled substance in bulk
for manufacture of analytical reference material which, in its final
form, is an exempted product.
Dated: July 15, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-15738 Filed 7-23-19; 8:45 am]
BILLING CODE 4410-09-P
